HCR Wealth Advisors Sells 7,645 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

HCR Wealth Advisors reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 71.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,061 shares of the financial services provider’s stock after selling 7,645 shares during the period. HCR Wealth Advisors’ holdings in iShares Biotechnology ETF were worth $405,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in IBB. Darwin Wealth Management LLC acquired a new position in iShares Biotechnology ETF in the 3rd quarter valued at $29,000. Highline Wealth Partners LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF in the third quarter valued at about $36,000. Modus Advisors LLC bought a new stake in iShares Biotechnology ETF during the fourth quarter worth about $41,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in iShares Biotechnology ETF during the third quarter worth about $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

IBB stock opened at $133.42 on Thursday. The company’s 50-day moving average price is $137.51 and its two-hundred day moving average price is $141.93. iShares Biotechnology ETF has a 12 month low of $123.60 and a 12 month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.